

Solid Tumors

A study of a medicine (GDC-0919) combined with another medicine (atezolizumab) in patients with cancer that has grown or spread

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT02471846 2015-001741-88
GO29779

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of GDC-0919 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy or for which standard therapy is ineffective, intolerable, or inappropriate. Participants will be enrolled in two stages, including a dose-escalation stage and an expansion stage.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT02471846 2015-001741-88 GO29779
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No

Researchers wanted to find out what dose of the study medicine (GDC-0919) was safe to combine with another medicine (atezolizumab). Both of these medicines have an effect on the immune system of the patient. The combination treatment was given to cancer patients to find out what effects, good and/or bad, GDC-0919 and atezolizumab had on patients and on their cancers. All patients received the same dose of atezolizumab; GDC-0919 was given at different doses to different groups of patients.